SLC5A2 and type 2 diabetes mellitus: To the best of our knowledge, this is the first case report in Saudi Arabia discussing the risk of EDKA associated with the use of GLP1 receptor agonists together with SGLT2 inhibitors and the extreme restriction of carbohydrate intake in patients with type 2 diabetes.